Vitamin D receptor ApaI, TaqI, BsmI, and FokI polymorphisms and psoriasis susceptibility: an updated meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Y. H. | - |
dc.date.accessioned | 2021-09-01T12:52:24Z | - |
dc.date.available | 2021-09-01T12:52:24Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 0307-6938 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/64249 | - |
dc.description.abstract | Background Vitamin D is considered a regulator of the immune system, and its polymorphisms have been associated with psoriasis in some but not all reports. Aim To explore whether vitamin D receptor (VDR) polymorphisms are associated with susceptibility to psoriasis. Methods Meta-analyses were conducted to determine the associations between psoriasis and the VDR ApaI, TaqI, BsmI and FokI polymorphisms in all participants, and stratified by ethnic group. Results In total, 16 studies on VDR polymorphisms and psoriasis were included in this meta-analysis, which involved 2086 patients and 2182 controls. The meta-analysis indicated an association between psoriasis and the VDR TaqI TT genotype in Caucasian (OR = 1.29, 95% CI = 1.00-1.66, P < 0.05), but not in Asian (OR = 1.32, 95% CI = 0.89-1.96, P = 0.16) populations. However, no association was found between psoriasis and the VDR TaqI polymorphism using dominant, allele contrast or homozygous contrast models. No association was found between psoriasis and either the VDR ApaI, BsmI or FokI polymorphisms by meta-analyses of the allele contrast, recessive, or dominant models or homozygous contrast models in the overall, Caucasian or Asian populations. Conclusion This meta-analysis showed that polymorphisms in VDR ApaI, BsmI and FokI are not associated with psoriasis susceptibility in overall, Caucasian or Asian populations. However, the VDR TaqI polymorphism is associated with psoriasis susceptibility in Caucasian populations. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | A-1012G PROMOTER POLYMORPHISM | - |
dc.subject | GENE POLYMORPHISMS | - |
dc.subject | CLINICAL-RESPONSE | - |
dc.subject | VDR GENE | - |
dc.subject | ASSOCIATION | - |
dc.subject | CALCIPOTRIOL | - |
dc.subject | RISK | - |
dc.subject | ALLELE | - |
dc.title | Vitamin D receptor ApaI, TaqI, BsmI, and FokI polymorphisms and psoriasis susceptibility: an updated meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Y. H. | - |
dc.identifier.doi | 10.1111/ced.13823 | - |
dc.identifier.scopusid | 2-s2.0-85057100898 | - |
dc.identifier.wosid | 000471312600017 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL DERMATOLOGY, v.44, no.5, pp.498 - 505 | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL DERMATOLOGY | - |
dc.citation.title | CLINICAL AND EXPERIMENTAL DERMATOLOGY | - |
dc.citation.volume | 44 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 498 | - |
dc.citation.endPage | 505 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | A-1012G PROMOTER POLYMORPHISM | - |
dc.subject.keywordPlus | GENE POLYMORPHISMS | - |
dc.subject.keywordPlus | CLINICAL-RESPONSE | - |
dc.subject.keywordPlus | VDR GENE | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | CALCIPOTRIOL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | ALLELE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.